Health Condition 1: I10- Essential (primary) hypertension
Conditions
Interventions
Intervention1: Text Messages: The study intervention will involve text messages, including a daily reminder to take anti-hypertensive medication and a weekly culturally tailored health education messa
Sponsors
NIL
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with a clinical diagnosis of hypertension. 2. Patients currently on anti-hypertensive therapy for a period of at least three months. 3. Systolic blood pressure equal to or greater than 140 mmHg and or diastolic blood pressure equal to or greater than 90 mmHg at enrolment. 4. Age 18 years and above. 5. Owning a mobile phone with access to text messaging service. 6. Willing to receive text messages at the specified time from the investigator.
Exclusion criteria
Exclusion criteria: 1. Patients with severe physical and cognitive impairment. 2. Pregnant and lactating women. 3. Inability to receive text messages due to patients not able to read in either English or their local language. 4. Frail older adults considered incapable of using anti-hypertensive medications without assistance. 5. Denial of informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Difference in systolic BP at 3 months follow up between the intervention arm and the control arm as assessed by the mean delta change from baseline. 2. Difference in medication adherence at 3 months follow up between the intervention arm and the control arm as assessed by the mean delta change from baseline.Timepoint: Three months (12 weeks) follow up from the date of randomization | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of individuals with at least 5 mmHg reduction in systolic BP from baseline to follow up between the intervention arm and the control arm.Timepoint: Three months (12 weeks) follow up from the date of randomization;Proportion of individuals with controlled hypertension defined as BP greater than 140 and 90 at 3 months follow up between the intervention arm and the control arm.Timepoint: Three months (12 weeks) follow up from the date of randomization | — |
Countries
India
Contacts
Public ContactDr Rohit Bhatia
All India Institute of Medical Sciences, New Delhi
Outcome results
None listed